InspireMD Aktie
WKN DE: A2PGJ7 / ISIN: US45779A8532
13.06.2025 19:24:18
|
InspireMD Announces CE Mark Approval For CGuard Prime Embolic Prevention System
(RTTNews) - InspireMD, Inc. (NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, announced Friday that the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard Prime EPS.
CGuard Prime was developed incorporating extensive user feedback and optimizes the deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet mesh, CGuard is designed to reduce both early and late embolic events by trapping debris against the vessel wall, preventing plaque prolapse and embolization that can cause stroke.
"Securing CE Mark certification under the EU MDR is a major milestone that demonstrates InspireMD's commitment to advancing our next generation platforms, regulatory rigor, and execution," said Marvin Slosman, CEO of InspireMD. "This approval clears the path for the commercial launch of CGuard Prime EPS across our current CE marked served markets, taking a pivotal step forward in our growth as a commercial-stage company and further strengthening our leadership in carotid stenting innovation."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu InspireMD Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |